Surveillance of adverse drug events associated with tocilizumab in hospitalized veterans with coronavirus disease 2019 (COVID-19) to inform patient safety and pandemic preparedness.
Rupak DattaAlexis BarrettMuriel BurkCedric SaloneAnthony AuFrancesca CunninghamAnn FisherLouise Marie DembryKathleen M AkgünPublished in: Infection control and hospital epidemiology (2021)
We evaluated adverse drug events (ADEs) by chart review in a random national sample of 428 veterans with coronavirus disease 2019 (COVID-19) who received tocilizumab (n = 173 of 428). ADEs (median time, 5 days) occurred in 51 of 173 (29%) and included hepatoxicity (n = 29) and infection (n = 13). Concomitant medication discontinuation occurred in 22% of ADE patients; mortality was 39%.
Keyphrases
- coronavirus disease
- adverse drug
- patient safety
- quality improvement
- electronic health record
- rheumatoid arthritis
- respiratory syndrome coronavirus
- public health
- end stage renal disease
- emergency department
- chronic kidney disease
- newly diagnosed
- drug induced
- sars cov
- ejection fraction
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- prognostic factors
- coronary artery disease
- risk factors
- infectious diseases